Stages and Progression of T1D

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

Most youth with type 1 diabetes in sub-Saharan Africa lack autoimmune markers, suggesting a distinct, non-autoimmune form of insulin-deficient diabetes.

Third-trimester hyperglycemia in pregnancy linked to adult obesity in children

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Third-trimester hyperglycemia in pregnancy linked to adult obesity in offspring | Image Credit: © lukszczepanski - stock.adobe.com.

Diabetes device data may fail to deliver based on smartphone settings

A 40-year study found that higher third-trimester glucose levels in insulin-dependent pregnancies were tied to increased obesity risk in adult offspring.

FDA approves first generic GLP-1 injection for type 2 diabetes in patients 10 years and up

The FDA is warning diabetes patients that information from CGMs, insulin pumps, and automated dosing systems could fail to be delivered if smartphone settings are not properly configured.

Patrick Campbell

Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Non-autoimmune diabetes common in African youth with T1D diagnosis

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Related Content

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

Most youth with type 1 diabetes in sub-Saharan Africa lack autoimmune markers, suggesting a distinct, non-autoimmune form of insulin-deficient diabetes.

Third-trimester hyperglycemia in pregnancy linked to adult obesity in children

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Diabetes device data may fail to deliver based on smartphone settings

A 40-year study found that higher third-trimester glucose levels in insulin-dependent pregnancies were tied to increased obesity risk in adult offspring.

FDA approves first generic GLP-1 injection for type 2 diabetes in patients 10 years and up

The FDA is warning diabetes patients that information from CGMs, insulin pumps, and automated dosing systems could fail to be delivered if smartphone settings are not properly configured.

Patrick Campbell

Afrezza inhaled insulin meets primary endpoint in phase 3 pediatric diabetes trial

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.